Canaccord analyst Richard Close maintained a Buy rating on Health Insurance Innovations and raised his price target to $62 from $55, saying revenue and adjusted EBITDA growth is likely to accelerate in 2019. Close said he has taken a conservative stance with the firm’s estimates as not to get too far ahead of the company, but overall he is encouraged with the growth opportunity and bias that estimates move higher as 2018 progresses.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.